Tammie L. S. Benzinger, MD, PhD
11
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Imaging Biomarkers in Preclinical and Symptomatic AD
Role: lead
Investigation of Inflammation Using [C-11]-CS1P1
Role: lead
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
Role: lead
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Role: lead
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
Role: lead
Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.
Role: lead
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
Role: lead
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
Role: lead
F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)
Role: lead
F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected
Role: lead
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
Role: lead
All 11 trials loaded